Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1601-1604

  Xu, Qiuyi ^a   Xu, Nong ^a   Fang, Weijia ^a   Zhao, Peng ^a   Mao, Chenyu ^a   Zheng, Yulong ^a   Mou, Haibo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Complete remission; Gemcitabine; Primary Fallopian tube carcinoma; Refractory

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LIVER METASTASIS; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVARY CYST; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SALPINGOOOPHORECTOMY; UTERINE TUBE CARCINOMA;

EID: 84875711915     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1232     Document Type: Article

References (24)

1. Riska A, Leminen A and Pukkala E: Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97. Int J Cancer 104: 643-645, 2003.
2. Markman M, Webster K, Zanotti K, Kulp B, Peterson G and BelinsonJ: Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90: 593-596, 2003.
3. Lorusso D, Di Stefano A, Fanfani F and Scambia G: Role of gemcitabine in ovarian cancer treatment. Ann Oncol 17 (Suppl5): v188-v194, 2006.
4. Stewart SL, Wike JM, Foster SL and Michaud F: The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 107: 392-397, 2007.
5. Ajithkumar TV, Minimole AL, John MM and Ashokkumar OS: Primary fallopian tube carcinoma. Obstet Gynecol Surv 60: 247-252, 2005.
6. Hefler LA, Rosen AC, Graf AH, et al: The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study. Cancer89: 1555-1560, 2000.
7. Wethington SL, Herzog TJ, Seshan VE, et al: Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 113: 3298-3306, 2008.
8. Rosen AC, Ausch C, Hafner E, et al: A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Eur J Cancer 34: 1725-1729, 1998.
9. Riska A and Leminen A: Updating on primary fallopian tube carcinoma. Acta Obstet Gynecol Scand 86: 1419-1426, 2007.
10. Papadimitriou CA, Peitsidis P, Bozas G, et al: Paclitaxel-and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience. Oncology 75: 42-48, 2008.
11. Gadducci A, Landoni F, Sartori E, et al: Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol 81: 150-159, 2001.
12. Pectasides D, Pectasides E, Papaxoinis G, et al: Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol 115: 97-101, 2009.
13. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG and Abeler VM: Carcinoma of the fallopian tube. Cancer 89: 2076-2084, 2000.
14. Tresukosol D, Kudelka AP, Edwards CL, Fromm GL, ManteR and Kavanagh JJ: Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel. Gynecol Oncol 58: 258-261, 1995.
15. Dunton CJ and Neufeld J: Complete response to topotecan of recurrent fallopian tube carcinoma. Gynecol Oncol 76: 128-129, 2000.
16. Matsuo K, Lin YG, Roman LD and Sood AK: Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 19: 1339-1354, 2010.
17. van Moorsel CJ, Pinedo HM, Veerman G, et al: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80: 981-990, 1999.
18. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S and Rodriguez M: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88: 17-21, 2003.
19. Nagourney RA, Brewer CA, Radecki S, et al: Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 88: 35-39, 2003.
20. Tewari D, Monk BJ, Hunter M, Falkner CA and Burger RA: Gemcitabine and cisplatin chemotherapy an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 22: 475-480, 2004.
21. Brewer CA, Blessing JA, Nagourney RA, Morgan M and HanjaniP: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103: 446-450, 2006.
22. Bozas G, Bamias A, Koutsoukou V, Efstathiou E, GikaD, Papadimitriou CA and Dimopoulos MA: Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 104: 580-585, 2007.
23. Rose PG: Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 15 (Suppl 1): 18-22, 2005.
24. Griffiths RW, Zee YK, Evans S, et al: Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer21: 58-65, 2011.